Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report.

Pantano N, Hunt B, Schwarz RA, Parra S, Cherry K, Possati-Resende JC, Longatto-Filho A, Fregnani JHTG, Castle PE, Schmeler K, Richards-Kortum R.

Photochem Photobiol. 2018 Jul 7. doi: 10.1111/php.12976. [Epub ahead of print]

PMID:
29981148
2.

Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador.

Maza M, Melendez M, Masch R, Alfaro K, Chacon A, Gonzalez E, Soler M, Conzuelo-Rodriguez G, Gage JC, Alonzo TA, Castle PE, Felix JC, Cremer M.

Prev Med. 2018 Jun 26;114:149-155. doi: 10.1016/j.ypmed.2018.06.017. [Epub ahead of print]

3.

Cervical Cancer Screening among Underscreened and Unscreened Brazilian Women: Training Community Health Workers to be Agents of Change.

Kienen N, Bittencourt L, Pelloso SM, Consolaro ME, Castle PE, Partridge EE, Silva NR, Scarinci IC.

Prog Community Health Partnersh. 2018;12(1S):111-119. doi: 10.1353/cpr.2018.0026.

PMID:
29755054
4.

Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology.

Yu K, Hyun N, Fetterman B, Lorey T, Raine-Bennett TR, Zhang H, Stamps RE, Poitras NE, Wheeler W, Befano B, Gage JC, Castle PE, Wentzensen N, Schiffman M.

J Natl Cancer Inst. 2018 Apr 11. doi: 10.1093/jnci/djy044. [Epub ahead of print]

PMID:
29659930
5.

Can a gastric cancer risk survey identify high-risk patients for endoscopic screening? A pilot study.

In H, Langdon-Embry M, Gordon L, Schechter CB, Wylie-Rosett J, Castle PE, Margaret Kemeny M, Rapkin BD.

J Surg Res. 2018 Jul;227:246-256. doi: 10.1016/j.jss.2018.02.053. Epub 2018 Apr 3.

PMID:
29622399
6.

Diagnosing Cervical Neoplasia in Rural Brazil Using a Mobile Van Equipped with In Vivo Microscopy: A Cluster-Randomized Community Trial.

Hunt B, Fregnani JHTG, Schwarz RA, Pantano N, Tesoni S, Possati-Resende JC, Antoniazzi M, de Oliveira Fonseca B, de Macêdo Matsushita G, Scapulatempo-Neto C, Kerr L, Castle PE, Schmeler K, Richards-Kortum R.

Cancer Prev Res (Phila). 2018 Jun;11(6):359-370. doi: 10.1158/1940-6207.CAPR-17-0265. Epub 2018 Apr 4.

PMID:
29618459
7.

Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium.

Doubeni CA, Gabler NB, Wheeler CM, McCarthy AM, Castle PE, Halm EA, Schnall MD, Skinner CS, Tosteson ANA, Weaver DL, Vachani A, Mehta SJ, Rendle KA, Fedewa SA, Corley DA, Armstrong K.

CA Cancer J Clin. 2018 May;68(3):199-216. doi: 10.3322/caac.21452. Epub 2018 Mar 30. Review.

8.

Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy.

Demarco M, Cheung LC, Kinney WK, Wentzensen N, Lorey TS, Fetterman B, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2018 Apr;22(2):97-103. doi: 10.1097/LGT.0000000000000382.

9.

Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.

Castle PE, Wheeler CM, Campos NG, Sy S, Burger EA, Kim JJ; New Mexico HPV Pap Registry Steering Committee.

Prev Med. 2018 Jun;111:177-179. doi: 10.1016/j.ypmed.2018.03.011. Epub 2018 Mar 14.

PMID:
29548787
10.

Charting the Future of Cancer Health Disparities Research-Letter.

Castle PE.

Cancer Res. 2018 Apr 1;78(7):1883-1885. doi: 10.1158/0008-5472.CAN-17-2932. Epub 2018 Mar 5. No abstract available.

PMID:
29506973
11.

Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.

Demarco M, Carter-Pokras O, Hyun N, Castle PE, He X, Dallal CM, Chen J, Gage JC, Befano B, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, Wentzensen N, Schiffman M.

J Clin Microbiol. 2018 Apr 25;56(5). pii: e01910-17. doi: 10.1128/JCM.01910-17. Print 2018 May.

PMID:
29491018
12.

Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years.

Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Katki HA, Locke A, Kinney WK, Castle PE.

Cancer Prev Res (Phila). 2018 Mar;11(3):165-170. doi: 10.1158/1940-6207.CAPR-17-0293. Epub 2018 Feb 5.

PMID:
29437696
13.

Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women.

Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, Castle PE, Wentzensen N, Burk RD.

Clin Cancer Res. 2018 May 1;24(9):2194-2202. doi: 10.1158/1078-0432.CCR-17-3251. Epub 2018 Feb 2.

PMID:
29420222
14.

Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.

Canfell K, Saville M, Caruana M, Gebski V, Darlington-Brown J, Brotherton J, Heley S, Castle PE.

BMJ Open. 2018 Jan 26;8(1):e016700. doi: 10.1136/bmjopen-2017-016700. Erratum in: BMJ Open. 2018 Mar 8;8(3):e016700corr1.

15.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

Clarke MA, Fetterman B, Cheung LC, Wentzensen N, Gage JC, Katki HA, Befano B, Demarco M, Schussler J, Kinney WK, Raine-Bennett TR, Lorey TS, Poitras NE, Castle PE, Schiffman M.

J Clin Oncol. 2018 Apr 20;36(12):1184-1191. doi: 10.1200/JCO.2017.75.3442. Epub 2018 Jan 22.

PMID:
29356609
16.

Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions.

Leinonen MK, Schee K, Jonassen CM, Lie AK, Nystrand CF, Rangberg A, Furre IE, Johansson MJ, Tropé A, Sjøborg KD, Castle PE, Nygård M.

J Clin Virol. 2018 Feb - Mar;99-100:22-30. doi: 10.1016/j.jcv.2017.12.008. Epub 2017 Dec 21.

17.

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.

Rendle KA, Schiffman M, Cheung LC, Kinney WK, Fetterman B, Poitras NE, Lorey T, Castle PE.

Prev Med. 2018 Apr;109:44-50. doi: 10.1016/j.ypmed.2017.12.023. Epub 2017 Dec 27.

PMID:
29288782
18.

Depth of Cervical Intraepithelial Neoplasia Grade 3 in Peruvian Women: Implications for Therapeutic Depth of Necrosis.

Taxa L, Jeronimo J, Alonzo TA, Gage J, Castle PE, Cremer ML, Felix JC.

J Low Genit Tract Dis. 2018 Jan;22(1):27-30. doi: 10.1097/LGT.0000000000000355.

PMID:
29271853
19.

A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix.

Castle PE, Pierz A, Stoler MH.

Gynecol Oncol. 2018 Feb;148(2):422-429. doi: 10.1016/j.ygyno.2017.12.001. Epub 2017 Dec 14. Review.

PMID:
29248196
20.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

Landy R, Cheung LC, Schiffman M, Gage JC, Hyun N, Wentzensen N, Kinney WK, Castle PE, Fetterman B, Poitras NE, Lorey T, Sasieni PD, Katki HA.

Prev Med. 2018 Jun;111:429-435. doi: 10.1016/j.ypmed.2017.12.004. Epub 2017 Dec 6.

21.

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Katki HA, Schiffman M.

Ann Intern Med. 2018 Jan 2;168(1):20-29. doi: 10.7326/M17-1609. Epub 2017 Nov 28.

PMID:
29181509
22.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE.

J Natl Cancer Inst. 2018 May 1;110(5):501-508. doi: 10.1093/jnci/djx225.

PMID:
29145648
23.

Anal Cancer Risk Among People With HIV Infection in the United States.

Colón-López V, Shiels MS, Machin M, Ortiz AP, Strickler H, Castle PE, Pfeiffer RM, Engels EA.

J Clin Oncol. 2018 Jan 1;36(1):68-75. doi: 10.1200/JCO.2017.74.9291. Epub 2017 Nov 15.

24.

Smoking and subsequent human papillomavirus infection: a mediation analysis.

Eldridge RC, Pawlita M, Wilson L, Castle PE, Waterboer T, Gravitt PE, Schiffman M, Wentzensen N.

Ann Epidemiol. 2017 Nov;27(11):724-730.e1. doi: 10.1016/j.annepidem.2017.10.004. Epub 2017 Oct 17.

PMID:
29107447
25.

Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.

Jeronimo J, Castle PE, Temin S, Denny L, Gupta V, Kim JJ, Luciani S, Murokora D, Ngoma T, Qiao Y, Quinn M, Sankaranarayanan R, Sasieni P, Schmeler KM, Shastri SS.

J Glob Oncol. 2016 Oct 12;3(5):635-657. doi: 10.1200/JGO.2016.006577. eCollection 2017 Oct.

26.

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.

Demarco M, Lorey TS, Fetterman B, Cheung LC, Guido RS, Wentzensen N, Kinney WK, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2017 Oct;21(4):261-267. doi: 10.1097/LGT.0000000000000343.

27.

Correspondence regarding Suba et al., human papillomavirus screening for low and middle-income countries.

Castle PE.

Prev Med. 2017 Dec;105:356. doi: 10.1016/j.ypmed.2017.06.030. Epub 2017 Sep 19. No abstract available.

PMID:
28939142
28.

Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.

Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M.

PLoS Med. 2017 Sep 19;14(9):e1002388. doi: 10.1371/journal.pmed.1002388. eCollection 2017 Sep.

29.

HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis.

Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B, Cullen M, Boland JF, Wentzensen N, Nelson CW, Raine-Bennett T, Chen Z, Bass S, Song L, Yang Q, Steinberg M, Burdett L, Dean M, Roberson D, Mitchell J, Lorey T, Franceschi S, Castle PE, Walker J, Zuna R, Kreimer AR, Beachler DC, Hildesheim A, Gonzalez P, Porras C, Burk RD, Schiffman M.

Cell. 2017 Sep 7;170(6):1164-1174.e6. doi: 10.1016/j.cell.2017.08.001.

PMID:
28886384
30.

The Cost-Effectiveness of Visual Triage of Human Papillomavirus-Positive Women in Three Low- and Middle-Income Countries.

Campos NG, Jeronimo J, Tsu V, Castle PE, Mvundura M, Kim JJ.

Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1500-1510. doi: 10.1158/1055-9965.EPI-16-0787. Epub 2017 Jul 14.

PMID:
28710075
31.

Treatment of cervical intraepithelial lesions.

Castle PE, Murokora D, Perez C, Alvarez M, Quek SC, Campbell C.

Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:20-25. doi: 10.1002/ijgo.12191. Review.

PMID:
28691333
32.

Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.

Cheung LC, Pan Q, Hyun N, Schiffman M, Fetterman B, Castle PE, Lorey T, Katki HA.

Stat Med. 2017 Sep 30;36(22):3583-3595. doi: 10.1002/sim.7380. Epub 2017 Jun 28.

PMID:
28660629
33.

Why does cervical cancer occur in a state-of-the-art screening program?

Castle PE, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Schiffman M.

Gynecol Oncol. 2017 Sep;146(3):546-553. doi: 10.1016/j.ygyno.2017.06.003. Epub 2017 Jun 10.

PMID:
28606721
34.

Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer.

Burger EA, Kim JJ, Sy S, Castle PE.

Clin Infect Dis. 2017 Sep 15;65(6):893-899. doi: 10.1093/cid/cix475.

PMID:
28531261
35.

Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?

Fokom Domgue J, Schiffman M, Wentzensen NH, Gage JC, Castle PE, Raine-Bennett TR, Fetterman B, Lorey T, Poitras NE, Befano B, Xie Y, Miachon LS, Dean M.

J Clin Microbiol. 2017 Aug;55(8):2348-2355. doi: 10.1128/JCM.00492-17. Epub 2017 May 17.

36.

Cervical cancer prevention in El Salvador (CAPE)-An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country.

Maza M, Alfaro K, Garai J, Velado MM, Gage JC, Castle PE, Felix J, Luciani S, Campos N, Kim J, Masch R, Cremer M.

Gynecol Oncol Rep. 2017 Mar 3;20:58-61. doi: 10.1016/j.gore.2017.02.011. eCollection 2017 May.

37.

Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines.

Schiffman M, Wentzensen N, Khan MJ, Castle PE, Chelmow D, Huh WK, Moscicki AB, Stockdale CK, Darragh TM, Silver M, Guido RS.

J Low Genit Tract Dis. 2017 Apr;21(2):87-90. doi: 10.1097/LGT.0000000000000300. No abstract available.

38.

Screening to Prevent Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.

Castle PE, Jeronimo J, Temin S, Shastri SS.

J Clin Oncol. 2017 Apr 10;35(11):1250-1252. doi: 10.1200/JCO.2016.71.6563. Epub 2017 Jan 30. No abstract available.

PMID:
28135111
39.

Scale-Up of an Human Papillomavirus Testing Implementation Program in El Salvador.

Cremer M, Maza M, Alfaro K, Morales Velado M, Felix J, Castle PE, Kim J, Gage JC.

J Low Genit Tract Dis. 2017 Jan;21(1):26-32. doi: 10.1097/LGT.0000000000000280.

40.

Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study.

Engesæter B, van Diermen Hidle B, Hansen M, Moltu P, Staby KM, Borchgrevink-Persen S, Vintermyr OK, Lönnberg S, Nygård M, Janssen EA, Castle PE, Christiansen IK.

BMC Infect Dis. 2016 Nov 24;16(1):698.

41.

Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary.

Jeronimo J, Castle PE, Temin S, Shastri SS.

J Oncol Pract. 2017 Feb;13(2):129-133. doi: 10.1200/JOP.2016.017889. Epub 2016 Nov 15. No abstract available.

PMID:
27845871
42.

Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.

Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LA, Myers O, Cuzick J, Wentzensen N, Kinney W, Castle PE, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Obstet Gynecol. 2016 Dec;128(6):1248-1257.

43.

A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

Grant BD, Smith CA, Castle PE, Scheurer ME, Richards-Kortum R.

Vaccine. 2016 Nov 4;34(46):5656-5663. doi: 10.1016/j.vaccine.2016.09.021. Epub 2016 Sep 22.

44.

Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management.

Castle PE, Aslam S, Behrens C.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1595-1599. Epub 2016 Sep 1.

45.

When Less is More.

Castle PE.

J Natl Cancer Inst. 2016 Oct 18;109(2). pii: djw240. Print 2017 Feb. No abstract available.

PMID:
27756809
46.

Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.

Benard VB, Castle PE, Jenison SA, Hunt WC, Kim JJ, Cuzick J, Lee JH, Du R, Robertson M, Norville S, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

JAMA Oncol. 2017 Jun 1;3(6):833-837. doi: 10.1001/jamaoncol.2016.3609.

47.

CK7 Immunohistochemistry as a Predictor of CIN1 Progression: A Retrospective Study of Patients From the Quadrivalent HPV Vaccine Trials.

Mills AM, Paquette C, Terzic T, Castle PE, Stoler MH.

Am J Surg Pathol. 2017 Feb;41(2):143-152. doi: 10.1097/PAS.0000000000000747.

PMID:
27680604
48.

The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.

Silver MI, Schiffman M, Fetterman B, Poitras NE, Gage JC, Wentzensen N, Lorey T, Kinney WK, Castle PE.

Cancer. 2016 Dec 1;122(23):3682-3686. doi: 10.1002/cncr.30277. Epub 2016 Sep 22.

49.

HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico.

Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, Castle PE, Robles C, Lazcano-Ponce E.

Salud Publica Mex. 2016 Apr;58(2):211-9.

50.

Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico.

McDonald YJ, Goldberg DW, Scarinci IC, Castle PE, Cuzick J, Robertson M, Wheeler CM.

J Rural Health. 2017 Sep;33(4):382-392. doi: 10.1111/jrh.12202. Epub 2016 Aug 24.

Supplemental Content

Loading ...
Support Center